Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Remifentanil Plus Ketamine for Dynamic Flexible Bronchoscopy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03613792
Recruitment Status : Not yet recruiting
First Posted : August 3, 2018
Last Update Posted : October 19, 2018
Sponsor:
Information provided by (Responsible Party):
Satya Krishna Ramachandran, Beth Israel Deaconess Medical Center

Brief Summary:
This randomized controlled pilot clinical trial will enroll patients undergoing dynamic flexible bronchoscopy will be randomized to receive one of the two anesthetic combinations described above. The study will determine if there is a difference when considering patient and physician and satisfaction when performing DFB. Also, safety and efficacy of the two pharmacological combinations (fentanyl + midazolam and remifentanil + ketamine) used will be evaluated.

Condition or disease Intervention/treatment Phase
Bronchoscopy Drug: Remifentanil Drug: Fentanyl Drug: Midazolam Drug: Ketamine Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Supportive Care
Official Title: Remifentanil Plus Ketamine Versus Midazolam Plus Fentanyl for Dynamic Flexible Bronchoscopy: Randomized Double-blind Clinical Trial
Estimated Study Start Date : March 1, 2019
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : December 31, 2019


Arm Intervention/treatment
Active Comparator: Remifentanil and Ketamine Group
Patients in Group 1 will receive remifentanil and ketamine. Remifentanil will be administered initially with a 1mcg/kg IV bolus followed by a continuous infusion, 0.1 to 0.15 mcg/kg/min IV (using ideal body weight) with titration to a maximum dose of 0.2 to 0.4 mcg/kg/min IV. Total dose of ketamine will be titrated from 10 to 40 mg, based on clinical judgment, and it will be recorded. Ketamine will be delivered using 2mL syringes, previously filled with ketamine in normal saline at a 10mg/mL concentration.
Drug: Remifentanil
Opioid analgesic

Drug: Ketamine
Analgesic

Active Comparator: Fentanyl and Midazolam
The patients in this group will receive fentanyl doses that range between 0.5 to 2 mcg/kg (25 - 50 mcg) IV bolus in combination with midazolam 1-5 mg bolus over at least 2 minutes as determined by attending anesthesiologist (not to exceed 2.5 mg / 2 min per package insert). Total dosing of fentanyl and midazolam may be titrated, based on clinical judgment, and it will be recorded. Maintenance, additional midazolam doses of 25% of total initial dose required to achieved desired sedation may be administered IV if additional sedation is considered necessary
Drug: Fentanyl
Opioid analgesic

Drug: Midazolam
Benzodiazepine
Other Name: Versed




Primary Outcome Measures :
  1. Patient Satisfaction with Sedation Instrument (PSSI) [ Time Frame: Two hours after procedure conclusion, prior to patient discharge from the hospital ]
    The primary outcome will be a difference in patient satisfaction with sedation, as determined by a 5-point difference in the PSSI questionnaire. The total score will be assessed by summing the responses to each question. In the scale, 0 will denote no satisfaction (worst outcome) and 100 will represent the greatest possible satisfaction (best outcome).


Secondary Outcome Measures :
  1. Numerical Rating Scale (NRS) for Discomfort [ Time Frame: Two hours after procedure conclusion, prior to patient discharge from the hospital ]
    Difference between both groups in terms of numerical rating scale (NRS) for discomfort associated with the procedure (as reported by the patient). In the scale, 0 will denote no discomfort (best outcome) and 5 will represent the greatest possible discomfort (worse outcome).

  2. ALDRETE score [ Time Frame: Two hours after procedure conclusion, prior to patient discharge from the hospital ]
    The ALDRETE score (global assessment of post-anesthetic condition) is used to assess patients' recovery after bronchoscopy at PACU

  3. Clinician Satisfaction with Sedation Instrument (CSSI) [ Time Frame: Two hours after procedure conclusion, prior to patient discharge from the hospital ]
    The total score will be assessed by summing the responses to each question. In the scale, 0 will denote no satisfaction (worst outcome) and 100 will represent the greatest possible satisfaction (best outcome).

  4. Severity of Cough [ Time Frame: Two hours after procedure conclusion, prior to patient discharge from the hospital ]
    A scale to address severity of cough during the procedure will be used when the bronchoscope pass through the vocal cords and at the level of the proximal trachea, distal trachea and main bronchi. This scale has three categories: Mild, single coughs; Moderate, more than one episode of cough that last less than 5 seconds; and Severe, cough more than 5 seconds

  5. Incidence of Complications [ Time Frame: Two hours after procedure conclusion, prior to patient discharge from the hospital ]
    Complications such as desaturation, hypotension, pain, nausea, bradycardia, need for artificial airway or mechanical ventilation and need to abort bronchoscopy will be documented. These will then be compared as percentage of complications.

  6. Duration of Dynamic Flexible Bronchoscopy [ Time Frame: Two hours after procedure conclusion, prior to patient discharge from the hospital ]
    Defined as the total time spent between initial insertion of flexible bronchoscope and final withdrawal of such.

  7. PACU Length of Stay [ Time Frame: Until discharge from the PACU, on average one hour ]
    Total time of PACU stay with each of the pharmacological combinations, defined as the period of time between initial PACU arrival and final home or floor discharge.

  8. Total Nebulized Lidocaine Dose [ Time Frame: Until discharge from the PACU, on average one hour ]
    Total dose requirement of nebulized lidocaine, pain medication and cough suppressors at PACU discharge.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Adult (>18 years-old)
  • Undergoing planned flexible bronchoscopy with dynamic maneuvers for Excessive Central Airway Collapse assessment at Beth Israel Deaconess Medical Center.

Exclusion criteria:

  • Patients with any past medical history of disease that would put them at risk of receiving one of the four proposed medications. This includes, but it's not limited to, allergies, advanced stage kidney disease, congestive heart failure and non-controlled hypertension.
  • With a known/documented history of opioid abuse at any point during life.
  • PO2< 60 mmHg or SO2 <85% on room air during any of the encounters with physicians between the moment of initial screening and the procedure itself.
  • PaCO2 >60 mmHg
  • Planned additional procedure(s) requiring general anesthesia after the dynamic bronchoscopy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03613792


Contacts
Layout table for location contacts
Contact: Satya Krishna Ramachandran, MD 617-667-5531 skrama@bidmc.harvard.edu
Contact: Ariel Mueller, MA 617-632-8056 almuelle@bidmc.harvard.edu

Locations
Layout table for location information
United States, Massachusetts
Beth Israel Deaconess Medical Center (BIDMC) Not yet recruiting
Boston, Massachusetts, United States, 02215
Contact: Satya Krishna Ramachandran, MD         
Sponsors and Collaborators
Beth Israel Deaconess Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Satya Krishna Ramachandran, MD Beth Israel Deaconess Medical Center

Layout table for additonal information
Responsible Party: Satya Krishna Ramachandran, Vice Chair of Quality and Safety, Associate Professor of Anaesthesia, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier: NCT03613792     History of Changes
Other Study ID Numbers: 2018P000023
First Posted: August 3, 2018    Key Record Dates
Last Update Posted: October 19, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Satya Krishna Ramachandran, Beth Israel Deaconess Medical Center:
dynamic
flexible

Additional relevant MeSH terms:
Layout table for MeSH terms
Ketamine
Fentanyl
Remifentanil
Midazolam
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Analgesics, Opioid
Narcotics
Adjuvants, Anesthesia
Hypnotics and Sedatives
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents